JP4116082B2 - 子宮頸ガンの検出のための方法および組成物 - Google Patents

子宮頸ガンの検出のための方法および組成物 Download PDF

Info

Publication number
JP4116082B2
JP4116082B2 JP51170698A JP51170698A JP4116082B2 JP 4116082 B2 JP4116082 B2 JP 4116082B2 JP 51170698 A JP51170698 A JP 51170698A JP 51170698 A JP51170698 A JP 51170698A JP 4116082 B2 JP4116082 B2 JP 4116082B2
Authority
JP
Japan
Prior art keywords
seq
cervical cancer
protein
sample
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP51170698A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001500609A (ja
JP2001500609A5 (https=
Inventor
ケイ． ケーシー，スーザン
オバール，ロバート
ウー，イン―ジェ
Original Assignee
マトリテック，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マトリテック，インコーポレイテッド filed Critical マトリテック，インコーポレイテッド
Publication of JP2001500609A publication Critical patent/JP2001500609A/ja
Publication of JP2001500609A5 publication Critical patent/JP2001500609A5/ja
Application granted granted Critical
Publication of JP4116082B2 publication Critical patent/JP4116082B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP51170698A 1996-08-30 1997-08-19 子宮頸ガンの検出のための方法および組成物 Expired - Fee Related JP4116082B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/705,660 1996-08-30
US08/705,660 US5858683A (en) 1996-08-30 1996-08-30 Methods and compositions for the detection of cervical cancer
PCT/US1997/014526 WO1998009170A2 (en) 1996-08-30 1997-08-19 Methods and compositions for the detection of cervical cancer

Publications (3)

Publication Number Publication Date
JP2001500609A JP2001500609A (ja) 2001-01-16
JP2001500609A5 JP2001500609A5 (https=) 2005-04-07
JP4116082B2 true JP4116082B2 (ja) 2008-07-09

Family

ID=24834422

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51170698A Expired - Fee Related JP4116082B2 (ja) 1996-08-30 1997-08-19 子宮頸ガンの検出のための方法および組成物

Country Status (9)

Country Link
US (4) US5858683A (https=)
EP (1) EP0923740B1 (https=)
JP (1) JP4116082B2 (https=)
AT (1) ATE332505T1 (https=)
AU (1) AU4073297A (https=)
CA (1) CA2263888C (https=)
DE (1) DE69736293T2 (https=)
ES (1) ES2268735T3 (https=)
WO (1) WO1998009170A2 (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303323B1 (en) 1997-10-21 2001-10-16 Cancer Research Campaign Technology Limited Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies
JP2000511291A (ja) * 1997-10-21 2000-08-29 キャンサー リサーチ キャンペーン テクノロジー リミティド 細胞の増殖異常の測定
GB9805477D0 (en) * 1998-03-13 1998-05-13 Oxford Glycosciences Limited Methods and compositions for diagnosis of rheumatoid arthritis
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
US7306926B2 (en) * 1998-07-01 2007-12-11 Mtm Laboratories Ag Method for detecting carcinomas in a solubilized cervical body sample
DE19855819C2 (de) * 1998-12-03 2001-02-15 Roche Diagnostics Gmbh Stabilisierung von Cytokeratin enthaltenden Kalibratoren
US6294349B1 (en) 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
US6379970B1 (en) * 1999-04-30 2002-04-30 The Arizona Board Of Regents On Behalf Of The University Of Arizona Analysis of differential protein expression
DE60035499T2 (de) 1999-05-17 2008-03-20 Cytyc Corp., Marlborough Identifizierung von material aus dem milchkanal der brust
CA2376831A1 (en) * 1999-06-29 2001-01-04 Intercet, Ltd. Human cancer virtual simulation system
WO2001042467A2 (en) * 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
AU2074101A (en) * 1999-12-08 2001-06-18 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
US6980674B2 (en) * 2000-09-01 2005-12-27 Large Scale Proteomics Corp. Reference database
US6539102B1 (en) 2000-09-01 2003-03-25 Large Scale Proteomics Reference database
AU2001288501A1 (en) * 2000-09-01 2002-03-22 Large Scale Proteomics Corporation Reference database
EP1202211A3 (en) * 2000-10-26 2004-12-22 Riken Genomic DNA analysis computer program
KR100426454B1 (ko) * 2000-11-28 2004-04-13 김진우 인간 원암 유전자 및 이에 의해 코드되는 단백질
KR100426453B1 (ko) * 2000-11-28 2004-04-13 김진우 인간 자궁경부암 2 원암 유전자 및 이에 의해 코딩되는단백질, 이를 포함하는 발현벡터 및 이 벡터로 형질전환된세포
US20030009293A1 (en) * 2001-01-09 2003-01-09 Anderson Norman G. Reference database
AUPR595601A0 (en) 2001-06-27 2001-07-19 International Diabetes Institute Hypoglycaemic peptides and methods of use thereof
KR100472746B1 (ko) * 2001-08-13 2005-03-07 김진우 원암 유전자 ｋｇ-20 및 이에 의해 코드되는 단백질
US20030138425A1 (en) * 2001-09-21 2003-07-24 Mather Jennie Powell Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
US7306925B2 (en) 2001-11-09 2007-12-11 Vanderbilt University Phage antibodies to radiation-inducible neoantigens
US7906102B2 (en) 2001-10-03 2011-03-15 Vanderbilt University Ligands to radiation-induced molecules
EP1333278B1 (en) 2002-02-01 2004-03-10 MTM molecular tools in medicine Methods for monitoring and prognosis of disease course of gastrointestinal tumors
KR100472747B1 (ko) * 2002-03-12 2005-03-09 김진우 인간 원암 유전자 및 이에 의해 코드되는 단백질
EP1369694A1 (en) * 2002-04-09 2003-12-10 MTM Laboratories AG Method for discrimination of metaplasias from neoplastic or preneoplastic lesions
ES2316501T3 (es) * 2002-05-21 2009-04-16 Mtm Laboratories Ag Moleculas marcadoras asociadas con tumores pulmonares.
KR20030094905A (ko) * 2002-06-10 2003-12-18 김진우 생쥐 발암유전자, 이에 의해 코드되는 단백질 및 이를포함하는 발현벡터
WO2004003203A1 (en) * 2002-06-29 2004-01-08 Jin-Woo Kim Human cervical cancer 5 protooncogene and protein encoded therein
AU2002345414A1 (en) * 2002-07-04 2004-01-23 Jin Woo Kim Human protooncogene 6 and protein encoded therein
DE60200248T2 (de) 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
EP1422526A1 (en) 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
US20040137551A1 (en) * 2003-01-13 2004-07-15 Markovic Nenad S. Cervical acid phosphatase - papanicolaou (CAP-PAP) test kit, method and accesories, processes for producing and using the same
US7291699B2 (en) * 2003-03-18 2007-11-06 The Regents Of The University Of Colorado Product and methods for diagnosis and therapy for cardiac and skeletal muscle disorders
US7361460B2 (en) * 2003-04-11 2008-04-22 Digene Corporation Approach to molecular diagnosis of human papillomavirus-related diseases
DE60300339T2 (de) * 2003-08-25 2006-04-13 Mtm Laboratories Ag Verfahren zum Nachweis von Karzinomen in solubilisierten zervikalen Körperproben
WO2005043166A1 (ja) * 2003-10-30 2005-05-12 Sysmex Corporation 子宮腺癌の診断薬及び腺癌細胞の検出方法
US20050202405A1 (en) * 2003-11-28 2005-09-15 Amshey Joseph W. Methods, compositions, and kits for protein crystallization
ATE549625T1 (de) * 2004-03-24 2012-03-15 Tripath Imaging Inc Verfahren und zusammensetzungen zum nachweis einer zervixerkrankung
US20050221399A1 (en) * 2004-03-30 2005-10-06 Sysmex Corporation Method for screening cervical cancer
US7183057B2 (en) * 2004-03-31 2007-02-27 Dermtech International Tape stripping methods for analysis of skin disease and pathological skin state
US7316904B1 (en) 2004-06-30 2008-01-08 Chromodynamics, Inc. Automated pap screening using optical detection of HPV with or without multispectral imaging
EP3072522B1 (en) 2005-01-06 2019-04-24 Novo Nordisk A/S Anti-kir combination treatments and methods
KR100689275B1 (ko) 2005-03-30 2007-03-08 김현기 인간 원암유전자 ｔｒｇ 및 이에 의해 코드되는 단백질
US7595380B2 (en) * 2005-04-27 2009-09-29 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
US20070015166A1 (en) * 2005-07-14 2007-01-18 Nilsen Thor W Lateral flow methods and devices for detection of nucleic acid binding proteins
US7632498B2 (en) 2005-12-19 2009-12-15 Tripath Imaging, Inc. MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
US8012678B2 (en) 2007-07-24 2011-09-06 Wisconsin Alumni Research Foundation Biomarkers for human papilloma virus-associated cancer
BRPI0913578A2 (pt) 2008-05-14 2017-06-06 Dermtech Int diagnose de melanoma e lentigo solar por análise de ácido nucléico
EP2638396B1 (en) 2010-11-12 2017-03-01 incellDX, Inc. Methods and systems for predicting whether a subject has a cervical intraepithelial neoplasia (cin) lesion from a suspension sample of cervical cells
WO2013019730A1 (en) 2011-07-29 2013-02-07 The Washington University Antibodies to tip-1 and grp78
CN110527728A (zh) * 2013-08-08 2019-12-03 纽约州州立大学研究基金会 作为子宫颈癌和存活期的生物标记物的角蛋白
WO2019161126A1 (en) 2018-02-14 2019-08-22 Dermtech, Inc. Novel gene classifiers and uses thereof in non-melanoma skin cancers
US10449261B2 (en) 2014-07-24 2019-10-22 Washington University Compositions targeting radiation-induced molecules and methods of use thereof
JP2019513752A (ja) * 2016-04-07 2019-05-30 ケース ウエスタン リザーブ ユニバーシティ 神経変性疾患を治療するためのｔｄｐ−４３のミトコンドリア局在化阻害剤
US11352436B2 (en) 2017-02-10 2022-06-07 Washington University Antibodies to TIP1 and methods of use thereof
WO2020198229A1 (en) 2019-03-26 2020-10-01 Dermtech, Inc. Novel gene classifiers and uses thereof in skin cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56145222A (en) * 1980-04-28 1981-11-11 Toshiyuki Hamaoka Improved antibody and its preparation
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
WO1985003132A1 (en) * 1984-01-06 1985-07-18 The Regents Of The University Of California Cytokeratin tumor markers and assays for their detection
JPS6284100A (ja) * 1985-10-08 1987-04-17 Dainabotsuto Kk 扁平上皮癌関連抗原に対する抗体及びその免疫学的利用法
US5273877A (en) * 1985-12-24 1993-12-28 Massachusetts Institute Of Technology Non-histological cell type determination
US4882268A (en) * 1985-12-24 1989-11-21 Massachusetts Institute Of Technology Method for determining tissue of origin and degree of malignancy of tumor cells
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
CA1340245C (en) * 1989-04-21 1998-12-15 John Samuel Monoclonal antibody for differentiation of squamous cell carcinoma antigens and method of use for same
DK51092D0 (da) * 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
AU658257B2 (en) * 1991-10-31 1995-04-06 Matritech, Inc. Nuclear matrix protein fluid assay
US5688511A (en) * 1991-11-05 1997-11-18 Board Of Regents, The University Of Texas System Cellular protein TDP-43 and regulation of HIV-1 gene expression
US5350835A (en) * 1991-11-05 1994-09-27 Board Of Regents, University Of Texas Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
DE69333377T2 (de) * 1992-06-22 2004-10-21 Matritech Inc Neuartige marker maligner zelltypen in der inneren nukleären matrix
AU5694694A (en) * 1992-12-02 1994-06-22 Denis F. Hochstrasser A method for detecting growing cells using translationally controlled tumor protein p21
US5547928A (en) * 1993-12-17 1996-08-20 Matritech, Inc. Methods and compositions for the detection of colon cancers
US5519003A (en) * 1994-02-01 1996-05-21 Board Of Trustees Of The Leland Stanford Junior University WD-40-derived peptides and uses thereof

Also Published As

Publication number Publication date
JP2001500609A (ja) 2001-01-16
ATE332505T1 (de) 2006-07-15
US6027905A (en) 2000-02-22
DE69736293T2 (de) 2007-06-14
WO1998009170A3 (en) 1998-04-23
EP0923740A2 (en) 1999-06-23
CA2263888C (en) 2004-10-26
DE69736293D1 (de) 2006-08-17
WO1998009170A2 (en) 1998-03-05
CA2263888A1 (en) 1998-03-05
US20050164313A1 (en) 2005-07-28
US6803189B2 (en) 2004-10-12
AU4073297A (en) 1998-03-19
US20030157482A1 (en) 2003-08-21
EP0923740B1 (en) 2006-07-05
ES2268735T3 (es) 2007-03-16
US5858683A (en) 1999-01-12

Similar Documents

Publication Publication Date Title
JP4116082B2 (ja) 子宮頸ガンの検出のための方法および組成物
EP1232177B1 (en) Methods and compositions for detection and treatment of breast cancer, based on breast cancer-associated polypeptides
US6218131B1 (en) Materials and methods for detection of breast cancer
US5627034A (en) Assay for carcinoma proliferative status by measuring NGAL expression level
EP1668149A1 (en) Diagnostic marker for ovarian cancer
WO2006089125A2 (en) Methods of detecting ovarian cancer
US20140072969A1 (en) Differential Diagnosis Of Cancer And Other Conditions Based On Expression Of p63
WO1995016919A2 (en) Methods and compositions for the detection of colon cancers
CN115698718A (zh) 胰腺癌的检测方法和检测试剂
US20020164664A1 (en) Detection and treatment of prostate cancer
WO2002078636A2 (en) Detection and treatment of colorectal cancer
AU2004270759A1 (en) Diagnostic marker for ovarian cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070613

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080325

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080417

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110425

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110425

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110425

Year of fee payment: 3

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110425

Year of fee payment: 3

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120425

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120425

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130425

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130425

Year of fee payment: 5

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130425

Year of fee payment: 5

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130425

Year of fee payment: 5

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130425

Year of fee payment: 5

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130425

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140425

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees